Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.45 |
| ▸ | CTSA | P10619 | 15/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.37 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.36 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21834285 | 0.91 | CYP2C9 (0.44) | SCN9ACTSAAKR1C3AKR1C2ELANE | |
| SCHEMBL21834248 | 0.86 | CTSA (0.52) | CTSA | |
| SCHEMBL21834307 | 0.85 | CTSA (0.43) | CTSAELANE | |
| SCHEMBL21834313 | 0.84 | CTSA (0.44) | CTSAELANE | |
| SCHEMBL21834293 | 0.84 | CTSA (0.42) | SCN9ACTSAAKR1C3AKR1C2AKR1B10 | |
| SCHEMBL21834283 | 0.83 | CTSA (0.48) | SCN9ACTSA | |
| SCHEMBL21834335 | 0.83 | CTSA (0.43) | CTSAELANE | |
| SCHEMBL23243881 | 0.82 | CTSA (0.44) | SCN9ACTSAAKR1C3AKR1C2AKR1B10 | |
| SCHEMBL21834245 | 0.80 | CTSA (0.41) | CTSAELANE | |
| SCHEMBL21834276 | 0.79 | CTSA (0.44) | CTSAELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020060299-A1 | COMPOUND CONTAINING OXADIAZOLE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 에스케이바이오팜 주식회사 | 2020-03-26 | — | — | WO | claimed |
| US-20250034101-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| US-12145914-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-11-19 | — | — | US | disclosed |
| US-20230150955-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-20230150955-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-20230150955-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-11603358-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-03-14 | — | — | US | disclosed |
| US-20220024886-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. | 2022-01-27 | — | — | US | disclosed |
| US-20220024886-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. | 2022-01-27 | — | — | US | disclosed |
| US-11053208-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-07-06 | — | — | US | disclosed |
| US-11053208-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-07-06 | — | — | US | disclosed |
| US-20210115001-A1 | Compound Having Oxadiazole And Pharmaceutical Composition Containing The Same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-04-22 | — | — | US | disclosed |
| US-20210115001-A1 | Compound Having Oxadiazole And Pharmaceutical Composition Containing The Same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-04-22 | — | — | US | disclosed |
| WO-2020060299-A1 | COMPOUND CONTAINING OXADIAZOLE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 에스케이바이오팜 주식회사 | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150955-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | OTC, OXA1L, ATP6V1B2 | SCN9A 556/4885CTSA 3755/4885AKR1C3 2239/4885 |
| US-20220024886-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | OTC, OXA1L, ATP6V1B2 | SCN9A 556/4885CTSA 3755/4885AKR1C3 2239/4885 |
| US-20250034101-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | OTC, OXA1L, ATP6V1B2 | SCN9A 556/4885CTSA 3755/4885AKR1C3 2239/4885 |
| US-11053208-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | OTC, OXA1L, ATP6V1B2 | SCN9A 556/4885CTSA 3755/4885AKR1C3 2239/4885 |
| US-20210115001-A1 | Compound Having Oxadiazole And Pharmaceutical Composition Containing The Same | OTC, OXA1L, ATP6V1B2 | SCN9A 556/4885CTSA 3755/4885AKR1C3 2239/4885 |
| US-11603358-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | OTC, OXA1L, ATP6V1B2 | SCN9A 556/4885CTSA 3755/4885AKR1C3 2239/4885 |
| US-12145914-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | OTC, OXA1L, ATP6V1B2 | SCN9A 556/4885CTSA 3755/4885AKR1C3 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.